AU2018279834B2 - Liquid dosage forms to treat cancer - Google Patents

Liquid dosage forms to treat cancer Download PDF

Info

Publication number
AU2018279834B2
AU2018279834B2 AU2018279834A AU2018279834A AU2018279834B2 AU 2018279834 B2 AU2018279834 B2 AU 2018279834B2 AU 2018279834 A AU2018279834 A AU 2018279834A AU 2018279834 A AU2018279834 A AU 2018279834A AU 2018279834 B2 AU2018279834 B2 AU 2018279834B2
Authority
AU
Australia
Prior art keywords
malate
polyethylene glycol
dose
auco
cabozantinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018279834A
Other languages
English (en)
Other versions
AU2018279834A1 (en
Inventor
Steven LACY
Gisela Schwab
Khalid Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2018279834A1 publication Critical patent/AU2018279834A1/en
Application granted granted Critical
Publication of AU2018279834B2 publication Critical patent/AU2018279834B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018279834A 2017-06-09 2018-06-08 Liquid dosage forms to treat cancer Active AU2018279834B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762517736P 2017-06-09 2017-06-09
US62/517,736 2017-06-09
US201762520768P 2017-06-16 2017-06-16
US62/520,768 2017-06-16
PCT/US2018/036703 WO2018227119A1 (en) 2017-06-09 2018-06-08 Liquid dosage forms to treat cancer

Publications (2)

Publication Number Publication Date
AU2018279834A1 AU2018279834A1 (en) 2020-01-16
AU2018279834B2 true AU2018279834B2 (en) 2024-05-23

Family

ID=62779087

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018279834A Active AU2018279834B2 (en) 2017-06-09 2018-06-08 Liquid dosage forms to treat cancer

Country Status (10)

Country Link
US (3) US11504362B2 (enExample)
EP (1) EP3634413A1 (enExample)
JP (1) JP7249962B2 (enExample)
KR (1) KR102647794B1 (enExample)
CN (1) CN110678180A (enExample)
AU (1) AU2018279834B2 (enExample)
CA (1) CA3065560A1 (enExample)
MX (1) MX2019014298A (enExample)
UA (1) UA126402C2 (enExample)
WO (1) WO2018227119A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4019498A1 (en) * 2011-02-10 2022-06-29 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
CN110678180A (zh) 2017-06-09 2020-01-10 埃克塞里艾克西斯公司 治疗癌症的液体剂型
EP4647127A3 (en) 2018-01-26 2025-12-17 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN115569137A (zh) 2018-06-15 2023-01-06 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2016019285A1 (en) * 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
ES2436888T3 (es) 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
EP2387563B2 (en) * 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
JP5843873B2 (ja) 2010-10-29 2016-01-13 トロイカ ファーマスーティカルズ リミテッド ビタミンｂ１２の鼻内用組成物
US20140179736A1 (en) 2011-05-02 2014-06-26 Exelixis, Inc. Method of Treating Cancer and Bone Cancer Pain
MX351133B (es) * 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
CA2880236C (en) 2012-07-27 2022-09-13 Antonius Martinus Gustave Bunt Efflux inhibitor compositions and methods of treatment using the same
EP3738952A1 (en) 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
CN106488768A (zh) 2014-04-25 2017-03-08 埃克塞里艾克西斯公司 治疗肺腺癌的方法
CN110678180A (zh) 2017-06-09 2020-01-10 埃克塞里艾克西斯公司 治疗癌症的液体剂型

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2016019285A1 (en) * 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
F. M. YAKES ET AL, "Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth", MOLECULAR CANCER THERAPEUTICS, 10,12, 2011, 2298 - 2308, DOI: 10.1158/1535-7163.MCT-11-0264 *
FRAUKE BENTZIEN ET AL: "In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer", THYROID., vol. 23, no. 12, 2013, 1569 - 1577, DOI: 10.1089/thy.2013.0137 *
Q YANG ET AL, "Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation.", BAOJ PHARM SCI, 2015, 1 - 20, URL:http://www.ncbi.nlm.nih.gov/pubmed/25688382 *
R. KURZROCK ET AL, "Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 29, no. 19, 2011, 2660 - 2666,DOI: 10.1200/JCO.2010.32.4145 *
S. LACY ET AL, "Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites", DRUG METABOLISM AND DISPOSITION, v 43, n 8, 2015, 1190-1207, DOI: 10.1124/dmd.115.063610 *

Also Published As

Publication number Publication date
CN110678180A (zh) 2020-01-10
MX2019014298A (es) 2020-02-03
BR112019025110A2 (pt) 2020-09-01
EP3634413A1 (en) 2020-04-15
KR20200014903A (ko) 2020-02-11
US20230301978A1 (en) 2023-09-28
US20200268737A1 (en) 2020-08-27
JP2020523317A (ja) 2020-08-06
US12016854B2 (en) 2024-06-25
US20240307367A1 (en) 2024-09-19
US11504362B2 (en) 2022-11-22
CA3065560A1 (en) 2018-12-13
UA126402C2 (uk) 2022-09-28
WO2018227119A1 (en) 2018-12-13
AU2018279834A1 (en) 2020-01-16
JP7249962B2 (ja) 2023-03-31
KR102647794B1 (ko) 2024-03-15

Similar Documents

Publication Publication Date Title
AU2018279834B2 (en) Liquid dosage forms to treat cancer
Abel et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
US12036224B2 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
JP2014521658A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
US12201610B2 (en) Compositions comprising aticaprant
JP2014512355A (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
EP4185291B1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
KR20240115224A (ko) 경구용 액상 엔잘루타마이드 조성물
EA043824B1 (ru) Жидкие лекарственные формы для лечения рака
BR112019025110B1 (pt) Composição farmacêutica líquida e seus usos
Kshirsagar et al. Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects
AU2015360620A1 (en) Treatment of multiple sclerosis with combination of laquinimod and a statin
Nash et al. A study of propoxyphene and salicylate concentrations in human plasma following the administration of propoxyphene napsylate and aspirin
CA2917600A1 (en) Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy
Micheal et al. An Evaluation of Relative Bioavailability of Anastrozole Tablets 1 mg in Healthy, Adult, Postmenopausal/Surgically Sterile Indian Female Human Subjects under Fasting Conditions
Wisch Microemulsions: A New Perspective in the Treatment of Paediatric and Geriatric Tuberculosis Patients
Mahesh et al. Pharmacokinetic and Bioequivalence Com-parison Between Lumefantrine Tablets 480mg: an Open Label, Balanced, Random-ized-sequence, Single-dose, Two-period Crossover Study in Healthy Male Volun-teers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)